The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection
Open accessAbstract
The ectodomain of matrix protein 2 (M2e) of influenza A virus is an attractive target for a universal influenza A vaccine: the M2e sequence is highly conserved across influenza virus subtypes, and induced humoral anti-M2e immunity protects against a lethal influenza virus challenge in animal models. Clinical phase I studies with M2e vaccine candidates have been completed. However, the in vivo mechanism of immune protection induced by M2e-carrier vaccination is unclear. Using passive immunization experiments in wild-type, FcRγ−/−, FcγRI−/−, FcγRIII−/−, and (FcγRI, FcγRIII)−/− mice, we report in this study that Fc receptors are essential for anti-M2e IgG-mediated immune protection. M2e-specific IgG1 isotype Abs are shown to require functional FcγRIII for in vivo immune protection but other anti-M2e IgG isotypes can rescue FcγRIII−/− mice from a lethal challenge. Using a conditional cell depletion protocol, we also demonstrate that alveolar macrophages (AM) play a crucial role in humoral M2e-specific immune protection. Additionally, we show that adoptive transfer of wild-type AM into (FcγRI, FcγRIII)−/− mice restores protection by passively transferred anti-M2e IgG. We conclude that AM and Fc receptor-dependent elimination of influenza A virus-infected cells are essential for protection by anti-M2e IgG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype Production
Snapper, C. M., & Paul, W. E. (1987) · Science · doi:10.1126/science.3107127 · Cited by 1,920
Rooijen, N. V., & Sanders, A. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90012-4 · Cited by 1,779
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Hobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,002
FcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
A universal influenza A vaccine based on the extracellular domain of the M2 protein
Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M., & Fiers, W. (1999) · Nature Medicine · doi:10.1038/13484 · Cited by 752
Self-citationThe Global Circulation of Seasonal Influenza A (H3N2) Viruses
Russell, C. A., Jones, T. C., Barr, I. G., Cox, N. J., Garten, R. J., Gregory, V., Gust, I. D., Hampson, A. W., Hay, A. J., Hurt, A. C., et al. (2008) · Science · doi:10.1126/science.1154137 · Cited by 729
The Effectiveness of Vaccination against Influenza in Healthy, Working Adults
Nichol, K. L., Lind, A., Margolis, K. L., Murdoch, M., McFadden, R., Hauge, M., Magnan, S., & Drake, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510053331401 · Cited by 673
Cited by
The human antibody response to influenza A virus infection and vaccination
Krammer, F. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0143-6 · Cited by 796
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
DiLillo, D. J., Palese, P., Wilson, P. C., & Ravetch, J. V. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84428 · Cited by 407
Traditional and New Influenza Vaccines
Wong, S.-S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 372
M2e-based universal influenza A vaccine
Fiers, W., De Filette, M., Bakkouri, K. E., Schepens, B., Roose, K., Schotsaert, M., Birkett, A., & Saelens, X. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.007 · Cited by 334
Self-citationNext-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.018 · Cited by 299
Toward a Universal Influenza Virus Vaccine: Prospects and Challenges
Pica, N., & Palese, P. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-145115 · Cited by 284
Kawahara, T., Takahashi, T., Oishi, K., Tanaka, H., Masuda, M., Takahashi, S., Takano, M., Kawakami, T., Fukushima, K., Kanazawa, H., et al. (2015) · Microbiology and Immunology · doi:10.1111/1348-0421.12210 · Cited by 125
Customized protein glycosylation to improve biopharmaceutical function and targeting
Van Landuyt, L., Lonigro, C., Meuris, L., & Callewaert, N. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.11.017 · Cited by 66
de Vries, R. D., Nieuwkoop, N. J., Pronk, M., de Bruin, E., Leroux-Roels, G., Huijskens, E. G. W., van Binnendijk, R. S., Krammer, F., Koopmans, M. P. G., & Rimmelzwaan, G. F. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.082 · Cited by 63
Kakkola, L., Denisova, O. V., Tynell, J., Viiliäinen, J., Ysenbaert, T., Matos, R. C., Nagaraj, A., Öhman, T., Kuivanen, S., Paavilainen, H., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.267 · Cited by 54
Self-citationde Vries, R. D., Nieuwkoop, N. J., van der Klis, F. R. M., Koopmans, M. P. G., Krammer, F., & Rimmelzwaan, G. F. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix546 · Cited by 39
Köhler, J., Breitbach, K., Renner, C., Heitsch, A.-K., Bast, A., van Rooijen, N., Vogelgesang, S., & Steinmetz, I. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.05.004 · Cited by 30
Self-citation
Metadata
- Authors
- El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N., Verbeek, S., Fiers, W., & Saelens, X.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01
- Volume
- 186
- Issue
- 2
- Pages
- 1022-1031
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1655706054
- Cited by
- 335
- References
- 43
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.